Sana Biotechnology (NASDAQ:SANA) Cut to “Strong Sell” at Wall Street Zen
by Scott Moore · The Cerbat GemWall Street Zen lowered shares of Sana Biotechnology (NASDAQ:SANA – Free Report) from a sell rating to a strong sell rating in a research note published on Saturday morning.
Several other research analysts have also recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sana Biotechnology in a research report on Tuesday, April 14th. Bank of America upped their price objective on Sana Biotechnology from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. Zacks Research cut Sana Biotechnology from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 3rd. HC Wainwright lowered their price objective on Sana Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a research report on Wednesday, March 4th. Finally, Wedbush upped their price objective on Sana Biotechnology from $6.00 to $7.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 14th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Sana Biotechnology has an average rating of “Moderate Buy” and a consensus price target of $8.20.
View Our Latest Research Report on Sana Biotechnology
Sana Biotechnology Trading Down 0.9%
Shares of SANA stock opened at $3.26 on Friday. The company has a market cap of $870.00 million, a P/E ratio of -3.36 and a beta of 2.06. The firm has a fifty day moving average price of $3.43 and a 200 day moving average price of $4.10. Sana Biotechnology has a 12 month low of $1.60 and a 12 month high of $6.55.
Sana Biotechnology (NASDAQ:SANA – Get Free Report) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.03). On average, equities analysts forecast that Sana Biotechnology will post -0.59 EPS for the current year.
Institutional Investors Weigh In On Sana Biotechnology
Hedge funds and other institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. raised its stake in Sana Biotechnology by 180.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,135,444 shares of the company’s stock worth $7,581,000 after acquiring an additional 1,375,029 shares in the last quarter. Baillie Gifford & Co. raised its stake in Sana Biotechnology by 13.6% during the 3rd quarter. Baillie Gifford & Co. now owns 11,436,503 shares of the company’s stock worth $40,600,000 after acquiring an additional 1,371,775 shares in the last quarter. Integral Health Asset Management LLC raised its stake in Sana Biotechnology by 33.3% during the 3rd quarter. Integral Health Asset Management LLC now owns 2,000,000 shares of the company’s stock worth $7,100,000 after acquiring an additional 500,000 shares in the last quarter. Rafferty Asset Management LLC purchased a new position in Sana Biotechnology during the 3rd quarter worth $951,000. Finally, KLP Kapitalforvaltning AS purchased a new position in Sana Biotechnology during the 3rd quarter worth $100,000. 88.23% of the stock is currently owned by institutional investors and hedge funds.
About Sana Biotechnology
Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.
The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.